Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 14
2004 13
2005 9
2006 6
2007 5
2008 1
2009 1
2010 1
2011 1
2012 2
2013 2
2014 1
2015 3
2016 3
2017 5
2018 5
2019 2
2020 6
2021 7
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. Szabados B, et al. Among authors: kockx m. Eur Urol. 2022 Aug;82(2):212-222. doi: 10.1016/j.eururo.2022.04.013. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577646 Clinical Trial.
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Nguyen-Duc A, Viale G, Molinero L, Emens LA. Rugo HS, et al. Among authors: kockx mm. J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743. doi: 10.1093/jnci/djab108. J Natl Cancer Inst. 2021. PMID: 34097070 Free PMC article. Clinical Trial.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: kockx m. Nat Med. 2019 Nov;25(11):1706-1714. doi: 10.1038/s41591-019-0628-7. Epub 2019 Nov 4. Nat Med. 2019. PMID: 31686036 Free article. Clinical Trial.
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR. Tsao MS, et al. Among authors: kockx m. J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22. J Thorac Oncol. 2018. PMID: 29800747 Free PMC article. Clinical Trial.
Autophagy in cardiovascular disease.
Martinet W, Knaapen MW, Kockx MM, De Meyer GR. Martinet W, et al. Among authors: kockx mm. Trends Mol Med. 2007 Nov;13(11):482-91. doi: 10.1016/j.molmed.2007.08.004. Epub 2007 Oct 29. Trends Mol Med. 2007. PMID: 18029229 Review.
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T, Montironi R, Lopez-Beltran A, Van Leenders G, Allory Y, De Ridder D, Claessens F, Kockx M, Akand M, Joniau S, Netto G, Libbrecht L. Gevaert T, et al. Among authors: kockx m. Semin Cancer Biol. 2018 Oct;52(Pt 2):216-227. doi: 10.1016/j.semcancer.2017.10.004. Epub 2017 Oct 12. Semin Cancer Biol. 2018. PMID: 29032188 Review.
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: kockx m. Nat Med. 2023 Dec;29(12):3271. doi: 10.1038/s41591-023-02312-9. Nat Med. 2023. PMID: 36944799 No abstract available.
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, Geens W, Klein S, Seynaeve L, Cras L, D'Haene N, Michotte A, Caljon B, Salmon I, Bruneau M, Kockx M, Van Dooren S, Vanbinst AM, Everaert H, Forsyth R, Neyns B. Duerinck J, et al. Among authors: kockx m. J Immunother Cancer. 2021 Jun;9(6):e002296. doi: 10.1136/jitc-2020-002296. J Immunother Cancer. 2021. PMID: 34168003 Free PMC article. Clinical Trial.
92 results